Insider Buying: Precision BioSciences, Inc. (NASDAQ:DTIL) Director Buys $13,722.80 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Melinda Brown acquired 3,016 shares of the business’s stock in a transaction that occurred on Thursday, December 26th. The shares were purchased at an average cost of $4.55 per share, for a total transaction of $13,722.80. Following the completion of the transaction, the director now directly owns 7,218 shares in the company, valued at $32,841.90. The trade was a 71.78 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Precision BioSciences Trading Down 10.6 %

Shares of NASDAQ DTIL opened at $3.81 on Thursday. The firm’s 50 day moving average price is $6.59 and its 200-day moving average price is $8.51. Precision BioSciences, Inc. has a 52-week low of $3.61 and a 52-week high of $19.43. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22. The company has a market cap of $29.23 million, a PE ratio of 63.51 and a beta of 1.41.

Hedge Funds Weigh In On Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC lifted its holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,974 shares of the company’s stock after purchasing an additional 19,088 shares during the quarter. Geode Capital Management LLC owned 0.86% of Precision BioSciences worth $591,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.